SEC Form 4 · accession 0001179022-15-000085

GALECTIN THERAPEUTICS INC · GALT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Mar 12, 2015

Accepted (ET)

Jul 8, 2015 · 4:58 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001133416

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Mar 12, 2015	A	1,784	$0.00	A	176,606	D
Common Stock^F1	Apr 8, 2015	A	26,395	$0.00	A	202,089	D
Common Stock^F2	holding	—	—		—	2,776,186	I	By 10X Fund L.P.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Stock Option (right to buy)^F4,F3	$6.48	Apr 8, 2015	D	7,408	D	—	Mar 24, 2016	Common Stock	7,408	D
Stock Option (right to buy)^F4,F5	$7.08	Apr 8, 2015	D	6,780	D	—	Jun 28, 2021	Common Stock	6,780	D
Stock Option (right to buy)^F4,F6	$3.59	Apr 8, 2015	D	16,714	D	—	Mar 28, 2023	Common Stock	16,714	D
Stock Option (right to buy)^F4,F7	$13.38	Apr 8, 2015	D	5,204	D	—	Jan 21, 2024	Common Stock	5,204	D

F1Amount reported includes shares acquired on May 13, 2015 and previously reported on a Form 4 filed on May 15, 2015.
F2Reporting person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Martin disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F3The option vested quarterly in eight equal installments beginning May 12, 2011.
F4The option was canceled by mutual agreement of the reporting person and Galectin Therapeutics, Inc. The reporting person received 26,395 shares of restricted common stock, reported in Table 1 of this Form 4, as consideration for the cancellation of options granted on March 24, 2011, June 28, 2011, March 28, 2013 and January 21, 2014.
F5The option vested as to one-eighth of the shares on June 28, 2011 and thereafter quarterly in seven equal installments beginning August 12, 2011.
F6The option vested quarterly in eight equal installments beginning on May 12, 2013.
F725% of the options vested on January 21, 2014, the grant date, with the remainder vesting ratably on a monthly basis over a three year period.